Deerfield Management Company, L.P. (Series C) Entrada Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 57,331 shares of TRDA stock, worth $1 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
57,331Holding current value
$1 Million% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding TRDA
# of Institutions
101Shares Held
28.1MCall Options Held
34.5KPut Options Held
16.4K-
Baker Bros. Advisors LP New York, NY4.87MShares$85.1 Million0.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$77.4 Million48.7% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$77.1 Million28.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.05MShares$53.3 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.71MShares$29.9 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $548M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...